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Abstract
Introduction: Little is known about rheumatoid arthritis in the black, particularly in Congolese, populations. Our
objective was to describe the phenotype and genotype of rheumatoid arthritis (RA) in Congolese.
Methods: All consecutive rheumatoid arthritis (RA) patients attending Kinshasa University Hospital in a three-year
time period were included. Demographics, clinical features and tobacco consumption were noted. Disease Activity
Score (DAS)-28 based on the erythrocyte sedimentation rate (ESR), Health Assessment Questionnaire (HAQ), anti-
citrullinated peptide antibodies (CCP) antibodies and rheumatoid factor (RF) were determined. Radiographs were
scored according to Sharp-van der Heijde. On a subset of patients and controls HLA-DRB1 typing was performed.
Results: A total of 114 females and 14 males aged 51.2 ± 14.9 were included. Mean duration of symptoms was
four years. Moderate tobacco consumption was reported in a minority of patients. DAS-28 at first visit was >5.1
and HAQ ≥0.5 in all patients. X-rays showed joint erosions and/or joint space narrowing, mostly of a moderate
grade in 55.8% of patients. Anti-CCP and/or RF were present in 48.6% of patients with available data (n = 72) and
in 3.0% of controls (n = 67). Radiographic changes and nodules were more frequent in RF or anti-CCP positive
patients. One copy of the shared epitope was found in 13 patients (35.1%) and 3 controls (12.5%). Two copies
were found in one patient (2.7%) and in one control (4.2%).
Conclusion: Congolese patients with RA consult long after disease onset. Despite this delay, the majority presents
without major damage and is RF, anti-CCP and SE negative. We put forward the hypothesis that besides different
environmental factors there is probably also a particular genetic risk profile in Congolese patients, different from
the HLA-DRB1 shared epitope.
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Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory
disease characterized by symmetric destructive arthritis
that is often associated with extra-articular and systemic
manifestations. We must also take into account an
important morbidity and socio-economic impact [1,2] of
this disease as well as an increased cardio-vascular mor-
tality [3-6]. Great strides have been made on RA in
recent years, including a better understanding of the
genetic aspects, environmental factors and the disease’s
pathogenesis, at least in the Western world. These
developments also concern the clinical approach, includ-
ing methods used to assess the impact of RA as well as
treatment principles, such as the early intensive therapy
and treat-to-target approach, and the use of biologicals.
In contrast, there are still few data on RA in many other
parts of the world. Little is known about the epidemiol-
ogy of RA in black Africa, its severity, the cross-cultural
validity of the different classification criteria and mea-
surement scores, the socio-economic aspects as well as
the genetic and/or environmental factors leading to the
disease. Therefore, just copying Western principles
might not be correct.
In the Democratic Republic of Congo very few studies
have been published on RA. In 2008, JJ Malemba and
JM Mbuyi-Muamba reported, in a retrospective study,
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that RA was rare and mild in its clinical presentation at
the University Hospital of Kinshasa (UHK) [7]. These
observations were in agreement with those reported by
Bwanahali et al. in 1995 [8]. But these studies did not
use “quantifiable” parameters to assess the severity of
RA, and the first mentioned study had a hiatus due to
its retrospective nature. In addition, no information was
given on the frequency of shared epitope (SE), smoking
and the possible influence of a tropical environment
with its specific background of infections. In a recent
epidemiological study [9] also, a rather mild phenotype
was suggested. The current study was initiated to
describe prospectively the phenotype and HLA-DRB1
genotype of newly diagnosed RA patients attending the
rheumatology unit of the UHK in order to assess the
severity of the disease in this part of the world and to
test the potential involvement of amino acids 70 to 74
in the third hypervariable region of HLA-DRB1 (SE).
Materials and methods
Patient characteristics
This study includes all patients who were received for the
first time in the rheumatology unit of the UHK in the per-
iod from 1 January 2008 to 31 December 2010, and who
fulfilled the 1987 American College of Rheumatology
(ACR) classification criteria for RA [10]. The approval of
the ethics committee of the University of Kinshasa and the
consent of patients and controls were obtained. The UHK
receives approximately 500 patients with rheumatic dis-
eases (new cases) per year. Osteoarthritis is diagnosed in
more than 50% of patients, systemic diseases, spondylar-
thropathies and crystal arthritis in approximately 25% of
patients, soft tissue rheumatism in 16%, osteoporosis and
septic arthritis are less frequent. The control group con-
sisted of patients suffering from other rheumatic diseases
(osteoarthritis, soft tissue rheumatism, osteoporosis): 59
women and 8 men aged between 18 and 74 years. The
clinical evaluation involved general aspects (fever, weight
loss), signs and localization of synovitis (small joints/large
joints, symmetric or not) and the duration of morning
stiffness. Typical joint deformities of RA were listed.
Extra-articular manifestations were also checked, including
rheumatoid nodules, sicca syndrome and symptoms of
systemic manifestations like pericarditis and lung or
pleural involvement. Tobacco consumption was registered.
At the initial visit and before prescribing anti-rheumatic
drugs, the Disease Activity Score (DAS-28) was calculated
[11] as well as the Health Assessment Questionnaire
(HAQ index) [12] to assess functional impairment. The
DAS-28 calculation was based on the erythrocyte sedi-
mentation rate after one hour. Items of the HAQ were
explained and translated by the investigator whenever
necessary. Radiographs of hands and feet in frontal plane
were performed to evaluate joint space narrowing and
erosions according to the Sharp score modified by van der
Heijde [13].
Detection of anti-citrullinated peptide antibodies and
rheumatoid factor
Patient characteristics
Blood samples were taken from a subset of the patients
(n = 72) before the start of anti-rheumatic drugs and
from controls (n = 67).
The samples were centrifuged at the time of collection
and serum was stored at -77°C. The anti-citrullinated
peptide antibodies (anti-CCP) were measured by fluor-
oenzyme immunoassay using reagents from the second
generation (Thermo Fisher, Freiburg, Germany) on an
Immuno CAP 250 instrument (Thermo Fisher). Rheu-
matoid factor (RF) was measured by nephelometry using
an Immage 800 instrument (Beckman-Coulter, Brea,
CA, USA) using reagents from Beckman-Coulter. Cut-
off values for European individuals were applied.
Hemoglobin concentration measurement
The hemoglobin was measured in patients and controls
by spectrophotometry using a molecular absorption
spectrophotometer (SP 2100 Spectrum, CHINCAN;
Shanghai, China).
HLA-DRB1 genotyping and allele classification
HLA-DRB1 typing was performed on a subset of
patients (n = 37) and a control group (n = 24). Genomic
DNA was extracted from EDTA peripheral blood sam-
ples with the QIAsymphony platform and the DNA
Mini or Midi Kits (Qiagen, Hilden, Germany). HLA-
DRB1 typing was performed using the sequence specific
oligo (SSO) PCR technique (Lifecodes HLA-DRB1 typ-
ing kit, Gen-Probe, San Diego, CA, USA) with locus
specific exon 2 amplification and hybridization on
colored microbeads (Luminex, Austin, TX, USA). Alter-
natively a sequence specific primer (SSP) PCR method
was used (HLA-DR low, Orelup, Vienna, Austria). Poly-
morphisms located in exon 3 were not resolved. The
presence of shared epitope alleles was determined for
patients and controls and the HLA-DRB1 alleles were
classified according to du Montcel et al. [14]. This clas-
sification takes into account the amino acids 70 to 74 of
HLA-DRB1. The highest risk for Caucasians was shown
for the S2/S3P combination followed by S2/S2, S3P/S3P,
S2L, S3P/L, L/L (in decreasing risk order). L is a combi-
nation group comprising the low risk groups S3D, S1
and X.
Statistical analysis
A Student’s t-test was used to compare data in patients
with and without available data for X-ray damage, RF or
anti-CCP. The odds ratios (OR) and the 95% confidence
intervals were calculated by logistic regression. Tests for
association of contingency tables were performed using
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the two-tailed Fisher’s exact test. A P-value <0.05 was
considered statistically significant.
Results
One hundred twenty-eight patients were included, 114
women and 14 men (sex ratio F/M of 8:1). This study
population represents 8.5% of all new patients attending
the rheumatology unit of the UHK in the three-year
study period. The clinical characteristics of the patients
are described in Table 1. The mean age of the patients
was 51 ± 14.9 years (range 18 to 80 years). The average
time between the onset of the symptoms and the first visit
was four years (range two months to nine years), and the
median delay was three years. Cigarette smoking was
reported in a minority of patients (two males). Nine ladies
reported to “snuff” tobacco powder through the nose. The
DAS-28 at the first consultation was over 5.1 in all
patients. A HAQ index >0.5 was reported in all but one
patient. The average hemoglobin was 11.5 ± 0.6 g/dl for
patients and 12.1 ± 0.6/dl for the control group; 31
patients (24.2%) had a hemoglobin concentration ≤10 g/dl.
Rheumatoid nodules and typical joint deformities were
found in 17 (13.3%) and 28 patients (21.8%), respectively,
interosseous muscle atrophy in 20 patients (15.6%), and
sicca syndrome in 2 patients (1.6%). Weight loss was men-
tioned by 60 patients (46.9%).
Radiographs of hands and feet were obtained in a sub-
group of patients only (n = 78). Forty-three (55.1%)
showed erosions and/or joint space narrowing. The aver-
age and median (P25, P75) values of the van der Heijde
score were 17.6 and 2.5 (0, 13) respectively. A very high
score (>100) was found in four patients. Anti-CCP anti-
bodies and RF were measured in 72 patients and 67 con-
trols. Anti-CCP antibodies were positive in 34 patients
(47.2%), RF in 25 patients (34.7%), and 2 controls were
anti-CCP+/RF+ (Table 2). Erosions and/or joint space
narrowing were observed in 63% of anti-CCP positive
patients whose X-ray of hands and feet were available,
and in 54.3% of anti-CCP negative patients. A total of 11/
13 patients with rheumatoid nodules had anti-CCP anti-
bodies with very high titers (>300 U/l).
Table 1 shows that the patients whose serologic and/
or radiographic data were available were similar to those
for whom these data were not obtained. All had sym-
metric arthritis, arthritis of hand joints and involvement
of at least three joint areas. No statistically significant
difference was observed between the average age of
patients whose X-rays were available compared to
patients without X-rays (P = 0.21) or between patients
with serological analyzes and patients without (P = 0.74).
HLA-DRB1 typing was performed in a subset of
patients (n = 37) and controls (n = 24). The most fre-
quent HLA-DRB1 alleles in the control group were
HLA-DRB1*15:03, 13:01/02, 03:01/02 and 11:01. There
was a very low carrier frequency of DRB1*04:01 and
DRB1*13:03 in our Congolese population (patient group
and controls). The SE alleles detected were DRB1*04:01,
*13:03, *01:01/02 and *10. One copy of the SE was
found in 13 patients (35.1%) and 3 controls (12.5%).
Two copies of the SE were found in 1 patient (2.7%)
and 1 control (4.2%).
The association of the anti-CCP, RF and HLA-DRB1
SE test with RA was calculated, as shown in Table 2.
The RF and anti-CCP tests have a high specificity (true
negatives) and positive predictive value (PPV) with an
OR = 17. 3 (P <0.0001) and OR = 29.1 (P <0.0001),
respectively. However, the sensitivity and negative pre-
dictive value of these DNA tests are significantly lower.
Although the HLA-DRB1 SE test had a specificity of
87% and a PPV of 81%, the OR was only 3.8 (95% CI
0.9 to 15.1) (P = 0.07). When the carrier status was
counted, the OR was 2.6 (95% CI 0.8 to 8.3) (P = 0.124).
The classification of HLA-DRB1 alleles according to du
Montcel et al. showed the rarity of S2 HLA-DRB1
alleles (Table 3). We also looked into the association
between the presence of the SE together with anti-CCP
antibodies or RF. Using an univariate regression analysis,
the association between SE and RF or SE and anti-CCP
antibodies could not be established (P >0.05) (Table 4).
Discussion
Our results indicate that in a three-year time period
8.5% of outpatients suffering from rheumatic diseases
and attending the rheumatology unit of the UHK were
diagnosed with RA. The relative RA frequency of 8.5%
observed in this study is higher than that reported in a
previous paper showing RA to affect 3.6% of the patients
attending the rheumatology unit of UHK from 1988 to
2002 [7]. This is probably because of the retrospective
nature of the latter study.
Table 1 Clinical characteristics of patients with X-ray and/or serology versus others
Patients Average age (years) Disease duration DAS-28 >5.1 Clinical presentation* Frequency of deformities
Without X-ray 53.3 ± 16.0 4.5 ± 2.4 100% 100% 21.6%
With X-ray 49.9 ± 14.0 3.5 ± 2.6 100% 100% 22.0%
Without serology 50.9 ± 15.3 4.1 ± 2.8 100% 100% 21.4%
With serology 51.6 ± 14.9 3.9 ± 2.9 100% 100% 22.2%
(*): symmetric arthritis, hand joints involvement and involvement ≥3 joint areas. DAS-28, Disease Activity Score 28
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Patients consulted following a rather long delay after
experiencing typical symptoms and all presented with a
high value of DAS-28. This may be attributed to several
factors: the poverty of the population with difficulties in
accessing and paying for healthcare, the use of traditional
medicine, and lack of information and education. It is,
therefore, understandable why many patients consult
only when symptoms become intolerable as a conse-
quence of high disease activity. The high DAS-28-ESR
scores in our patient population are probably partly
related to the low hemoglobin level found in this study.
These low hemoglobin levels may not necessarily be
related to the severity of the RA since they are similar in
patients and controls. They are probably influenced by
the nutritional deficit and tropical infections which affect
a part of the Congolese population. Therefore, it is prob-
ably unwise to compare DAS-28-ESR scores from Congo-
lese patients in absolute terms with scores obtained in a
Western population. We cannot exclude that DAS-28-
CRP would have allowed a more accurate interpretation
of the disease activity, but unfortunately, for practical rea-
sons, CRP could not be determined.
Mean HAQ index was rather high, probably related to
the disease activity, but rheumatoid nodules and typical
deformities were found in less than 20% of patients.
Erosions and joint space narrowing were found in
somewhat more than 50% of patients and were of low
to moderate severity, taking into account the high dis-
ease activity and important delay before treatment.
The fact that more than 50% of Congolese RA patients
are RF and anti-CCP negative may contribute to the mild-
ness of the disease phenotype since the level of anti-CCP
and RF titers is linked with the disease severity [15-17]. A
mild phenotype was also reported in other African popula-
tions. Adewolo et al. [18] observed that in 200 patients fol-
lowed for RA in Nigeria only 38.5% were RF positive and
29% had joint erosions on radiographs of hands, while the
average duration of symptoms was 63 months before the
first consultation. Ndongo S et al. [19] in Senegal reported
that joint erosions were present in one-third of patients
and that extra-articular manifestations were very rare,
while the average time from the onset of symptoms
to initiation of disease modifying antirheumatic drugs
was 54 months. Anaya JM et al. [20] in Colombia have
described that RA was less severe in blacks than Mestizos
in terms of radiographic damage. Recently, Singwe-
Ngandeu et al. in Cameroon have also reported a mild
presentation of RA among their patients [21].
RF and anti-CCP were observed in only a few controls
(2.98%) in our study, whereas in this population, higher
numbers were expected due to the high frequency of
parasitic and viral infections. Using European cut-off





PPV NPV Specificity sensitivity OR 95% CI P-value
SE positive 35.1 (13) 12.5 (3) 81 47 87 35 3.8 0.9 to 15.1 0.07
negative 64.9 (24) 87.5 (21)
RF positive 34.7 (25) 3.0 (2) 93 58 97 35 17.3 3.9 to 76.6 <0.0001
negative 65.2 (47) 97.0 (65)
anti-CCP positive 47.2 (34) 3.0 (2) 94 63 97 47 29.1 6.6 to 127.9 <0.0001
negative 52.7 (38) 97.0 (65)
Anti-CCP, anti-cyclic citrullinated peptide; NPV, negative predictive value; PPV, positive predictive value; RA, rheumatoid arthritis; RF, rheumatoid factor; SE, shared
epitope
Table 3 HLA-DRB1 alleles classified according to du Montcel et al.
du Montcel
classification
Amino acid sequence positions
70 to 74




SE OR 95% CI P-value




S3P QRRAA *01:01/02 14.9 (11) 4.2 (2)
RRRAA *10
S1 DERAA *11:02, *13:01/02 81.0 (60) 91.6 (44) negative
QARAA *15
S3D DRRAA *11:01, *12, *16
X nonXXRAA *03,*07,*08,*09,
*14
[14], in RA patients and controls (homozygous alleles are counted double)
OR, odds ratio; RA, rheumatoid arthritis; SE, shared epitope; A, alanin; D, aspartic acid aspartique; E, glutamic acid; K, leucin; Q, glutamin; R, arginin
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values for RF and anti-CCP antibodies, as done in this
study, may be a problem in a sub-Saharan African
population and for future studies it would be advisable
to determine local cut-off values.
In our study there does not seem to be an association
between the presence of the shared epitope and RF or
anti-CCP antibodies (Table 4). Classic HLA-DRB1 S2 and
S3P epitopes were very rare. Singwe-Ngandeu M et al.
[21] observed also a discrepancy in a group of RA patients
in Cameroon of whom more than 75% were RF positive
and anti-CCP positive, but only 30% were carriers of the
S2 and S3P HLA-DRB1 alleles. The four most frequent
HLA-DRB1 alleles in our control group are those typically
reported in sub-Saharan Africa [22].
Interestingly, there was a low prevalence of HLA-
DRB1*04:01 in this study population (patients and controls)
compared to other populations [23,24]. This observation is
in agreement with that of Mbayo et al. [25,26], who
reported that HLA-DR4 was less frequent in Congolese
blood donors. This may be important since some authors
have reported that HLA-DRB1*04:01 (S2) is associated with
the most severe phenotype of RA [23,27]. Other HLA-
DRB1 alleles, on the contrary, were more prevalent. In
agreement with the study of Mbayo [25,26], we observed a
high frequency of HLA-DRB1*15: 03 (X), DRB1*13:01/02
(S1) and DRB1*11:01 (S3D). The lower risk of these HLA-
DRB1 alleles is confirmed in different studies [28-34].
The present study showed that 35.1% of the study RA
population had S2 and S3P HLA-DRB1 alleles. However,
compared to the control group, the association of SE
with RA was statistically not significant. Singwe-Ngandeu
et al. in Cameroon observed a lower frequency (30%) of
SE-positive cases among RA patients [21]. A low fre-
quency of HLA-DRB1 SE in blacks was also observed by
LB Hughes et al. [35], who reported a frequency of 25.2%
in African American patients. They found a high degree
of European ancestry among African Americans with SE
alleles, which suggests that a genetic risk factor for RA
was introduced into the African American population
through admixture. This is not in agreement with the
study of PWA Meyer et al. [36] who reported a frequency
of 59% of high-risk SE alleles in a predominant black
South African female population with RA, and this fre-
quency is similar to that reported by Barnetche et al. in a
Caucasian population [37]. When considering our results,
we cannot exclude that other genetic factors may be
involved in Congolese RA patients. This needs further
evaluation.
The effect of the environment on the incidence and
phenotype of RA must also be considered. Smoking,
the main environmental risk factor implicated in RA
[38-40], is present only in a small proportion of our
patients, and at a low level. Moreover, for cultural rea-
sons women very rarely smoke in DR Congo. Beyond
the effect of smoking, other environmental factors
could be implicated. Previous studies conducted in
sub-Saharan Africa have suggested a protective role of
malaria against autoimmune diseases. This applies to
the study of Greenwood [41] in Nigeria who observed
that mice infected with Plasmodium falciparum
showed fewer autoimmune disorders than mice free of
P. falciparum. Similarly, Moolenburgh [42] in Lesotho
observed that RA was more frequent and severe in
areas of high altitude than on the warmer plains with
more malaria. A similar survey in DR Congo could
help to clarify this concept, and it remains to be seen
whether the tropical environment with its many para-
sites could interfere with the phenotype of RA or be
implicated in the pathogenesis of the disease.
Disease classification, disease activity and functionality
of RA were evaluated in this paper using standardized
methods that are classical for evaluation of patients seen
in the Western world. Unfortunately, mainly because of
the cost issue, detailed serology data and genetic typing
were not feasible in all patients. Nevertheless, this study
will provide a benchmark for measuring benefits of RA
care in central Africa and will allow comparing disease
patterns in rural compared to this urban population in
the future. These preliminary results also make clear that
perhaps specific validation is needed for classification cri-
teria outside the Western world. For instance, the very
recent new classification criteria for RA [43] are of no
use in a specific situation where CRP and CCP measure-
ment is not performed in daily practice and where inten-
sive treatment and a treat-to-target approach are
currently unrealistic goals. We also found aspects of tim-
ing (duration of morning stiffness, six weeks symptom
duration) sometimes problematic to evaluate, as time
Table 4 Relation between shared epitope, anti-CCP and RF in Congolese RA patients
RA patient group OR 95% CI P-value
SE positive SE negative
anti-CCP positive 7 1 1.6 0.35 to 7.11 0.712
negative 4 10
RF positive 4 9 0.76 0.17 to 3.4 1.0
negative 7 12
Anti-CCP, anti-cyclic citrullinated peptide; RA, rheumatoid arthritis; RF, rheumatoid factor
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perceptions are different compared to the Western world.
Also proper cross-cultural validation of instruments like
the HAQ needs to be carried out, not only because of
translation issues, but also because of content problems;
for instance, with concepts like ‘shampooing hair’ which
is not often done by Congolese women.
Conclusion
In conclusion, the current preliminary data on the
phenotype and genotype of RA are the first from this
part of the world and according to our findings, we
put forward the hypothesis that the particular genetic
profile of RA in Western Europe is not present in sub-
Saharan Africans and this could explain the decreased
severity of the disease. A study in a larger sample
population is needed to better assess the impact of
HLA-DRB1alleles on the prevalence and phenotype of
RA in Congolese, and the correlation between the
shared epitope and the presence and titers of anti-CCP
and RF.
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